Ionis Pharmaceuticals

Last updated
Ionis Pharmaceuticals, Inc.
FormerlyIsis Pharmaceuticals, Inc.
Type Public company
Industry Biotechnology
Founded1989;34 years ago (1989)
FounderStanley T. Crooke
Headquarters Carlsbad, California, U.S.
Key people
Brett P. Monia (CEO) [1]
Elizabeth L. Hougen (CFO) [2]
Joseph Loscalzo
(Chairman of the Board) [3]
Products nusinersen, inotersen, volanesorsen, plazomicin, mipomersen
RevenueDecrease2.svg US$587 million (2022)
Decrease2.svgUS$−270 million (2022)
Total assets Decrease2.svg US$2.53 billion (2022)
Total equity Decrease2.svg US$573 million (2022)
Number of employees
796 (December 2022)
Website ionispharma.com
Footnotes /references
[4]

Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen) and has 4 drugs in pivotal studies: tominersen for Huntington’s disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis. [4]

Contents

The company was named Isis Pharmaceuticals until December 2015. [5]

History

The company was founded in 1989 as Isis Pharmaceuticals by Stanley T. Crooke, a former head of research of GlaxoSmithKline, with a goal to commercialize antisense therapy. [6]

In 1992, the company received its first approval by the Food and Drug Administration for an investigational new drug application in 1992 for a genital warts drug candidate. The FDA approval marked the first time for the company to conduct any antisense therapy and to be tested in humans. [7]

In 1995, the genital warts drug failed in clinical trials and Isis terminated development. By that time, Gilead Sciences had left the antisense therapy field, leaving only Isis, Hybridon, Genta and Lynx Therapeutics working in the field. [8] Gilead sold its patents, developed around antisense, to Isis. [9]

In December 2015, Isis changed its name to Ionis, driven in part by the negative image of "Isis" generated by the terrorist group, Islamic State of Iraq and the Levant, commonly known as ISIL or ISIS. [5] [10]

In 2017, the company completed the corporate spin-off of its rare lipid disorder subsidiary, Akcea Therapeutics. [11]

Products

The company's first marketed drug was fomivirsen (Vitravene, used in the treatment of cytomegalovirus retinitis (CMV) in immunocompromised patients. [12] It was discovered at the NIH and was licensed and initially developed by Isis, which subsequently licensed it to Novartis. [13] It was approved by the FDA for CMV in Aug 1998 as the first antisense drug. [14] Novartis withdrew the marketing authorization for fomivirsen in the EU in 2002 [15] and in the US in 2006. The drug was withdrawn as the development of HAART dramatically reduced the number of cases of CMV rinitis. [13]

The antisense field anticipated that the approval of fomivirsen marked the beginning of a new age of antisense drug treatments that would be similar to the uptake of monoclonal antibody therapy, but the next FDA approval of an antisense drug came in 2013. [14] Part of what held up all companies in the field was the way that the oligomers were chemically modified to prevent hydrolysis also reduced affinity to the antisense molecules' targets; by 2004 the field was shifting to second generation modifications. [16] Clinical trials of antisense therapeutics by all the companies in the early 2000s were also plagued by lack of efficacy and immune reactions to drug candidates. [17] Isis cut its workforce by 40% in 2005 due to weak sales of fomivirsen and lack of confidence by the market in antisense technology. [18]

In 2007, Isis and Alnylam Pharmaceuticals, which focuses on RNA interference, formed a 50/50 joint venture, Regulus Therapeutics, to apply their intellectual property and knowledge around oligomer biotherapeutics to micro-RNA targets. [19]

In 2008, Isis and Genzyme entered into a partnered drug candidate mipomersen (Kynamro), intended to treat homozygous familial hypercholesterolemia, and other drug candidates [ which? ]; the deal included Genzyme buying $150 million of Isis stock and paying a $175 million license fee, as well as milestone fees and royalties. [20] Mipomersen was rejected by the European Medicines Agency in 2012 [21] and again in 2013; [22] it was approved by the FDA in 2013. [14] In January 2016, Ionis terminated its arrangement with Genzyme, stating that the drug had been poorly marketed. [23] In May 2016, Ionis licensed the rights to the drug to Kastle Therapeutics for $15 million upfront with another $10 million due in May 2019, up to $70 million in milestones based on sales, and royalties, with Ionis paying 3% royalty and 3% of non-cash royalty it receives to Genzyme. [24] Mipomersen has still not been approved in Europe. [17]

In December 2016, Ionis's drug nusinersen (Spinraza) was approved by the FDA. [25] It had been discovered in a collaboration between Adrian Krainer at Cold Spring Harbor Laboratory and Ionis (then Isis) [26] [27] [17] [28] and preclinical work was done at University of Massachusetts. [29] The drug was initially developed by Ionis, which partnered with Biogen on development starting in 2012; in 2015 Biogen acquired an exclusive license to the drug for a $75 million license fee, milestone payments up to $150M, and tiered royalties between 10 and 15% thereafter; Biogen also paid for all development subsequent to taking the license. [30] The license to Biogen included licenses to intellectual property that Ionis had acquired from Cold Spring Harbor and University of Massachusetts. [31]

As of December 2016, Ionis had ten candidates for various liver diseases in clinical trials and a drug it discovered, alicaforsen, was in a Phase III trial run by another company. [17] It also had a huntingtin gene-lowering antisense molecule for Huntington's disease in clinical trial. [32]

Related Research Articles

<span class="mw-page-title-main">Biogen</span> Pharmaceutical company

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.

Antisense therapy is a form of treatment that uses antisense oligonucleotides (ASOs) to target messenger RNA (mRNA). ASOs are capable of altering mRNA expression through a variety of mechanisms, including ribonuclease H mediated decay of the pre-mRNA, direct steric blockage, and exon content modulation through splicing site binding on pre-mRNA. Several ASOs have been approved in the United States, the European Union, and elsewhere.

<span class="mw-page-title-main">Vertex Pharmaceuticals</span> American pharmaceutical company

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in South Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.

Takeda Oncology is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.

<span class="mw-page-title-main">Genzyme</span> Company

Genzyme was an American biotechnology company based in Cambridge, Massachusetts. Since its acquisition in 2011, Genzyme has been a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world's third-largest biotechnology company, employing more than 11,000 people around the world. As a subsidiary of Sanofi, Genzyme has a presence in approximately 65 countries, including 17 manufacturing facilities and 9 genetic-testing laboratories. Its products are also sold in 90 countries. In 2007, Genzyme generated $3.8 billion in revenue with more than 25 products on the market. In 2006 and 2007, Genzyme was named one of Fortune magazine’s “100 Best Companies to Work for”. The company donated $83 million worth of products worldwide; in 2006, it made $11 million in cash donations. In 2005, Genzyme was awarded the National Medal of Technology, the highest level of honor awarded by the president of the United States to America's leading innovators. In February 2022, Sanofi's new corporate brand was unveiled and former entity "Sanofi Genzyme" got integrated into Sanofi.

<span class="mw-page-title-main">Fomivirsen</span> Antiviral drug

Fomivirsen is an antisense antiviral drug that was used in the treatment of cytomegalovirus retinitis (CMV) in immunocompromised patients, including those with AIDS. It was administered via intraocular injection.

Ustekinumab, sold under the brand name Stelara, is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, targeting both IL-12 and IL-23.

<span class="mw-page-title-main">Mipomersen</span> Drug used to treat genetic hypercholesterolemia

Mipomersen is a drug used to treat homozygous familial hypercholesterolemia and is administered by subcutaneous injection. There is a serious risk of liver damage from this drug and it can only be prescribed in the context of a risk management plan.

<span class="mw-page-title-main">Genta (company)</span>

Genta Incorporated was a biopharmaceutical company started in La Jolla, California, which discovered and developed innovative drugs for the treatment of patients with cancer. Founded in 1989 by a highly skilled entrepreneur, the company focused on a novel technology known as antisense, which targets gene products that are associated with the onset and progression of serious diseases. At that time, only Ionis Pharmaceuticals, Inc. was conducting significant research with this technology. Antisense is a short span of oligonucleotides – modified DNA structures ranging from about 12-24 bases that selectively bind to specific RNA. The intent is to block expression of an aberrant protein that contributes to the disease of interest. Genta in-licensed three different antisense molecules that blocked Bcl-2, a fibroblast growth factor (FGF), and the gene c-myb, respectively.

Santaris Pharma A/S was a biopharmaceutical company founded in 2003 in Copenhagen, Denmark. The company also had a branch in San Diego, California that opened in 2009. Created by a merger between Cureon and Pantheco, Santaris developed RNA-targeted medicines using a Locked Nucleic Acid (LNA) Drug Platform and Drug Development Engine.

<span class="mw-page-title-main">Alicaforsen</span> Chemical compound

Alicaforsen is an antisense oligonucleotide therapeutic that targets the messenger RNA for the production of human ICAM-1 receptor and is being developed for the treatment of acute disease flares in moderate to severe Inflammatory Bowel Disease (IBD).

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

<span class="mw-page-title-main">Henri Termeer</span>

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

<span class="mw-page-title-main">Nusinersen</span> Medication used for spinal muscular atrophy

Nusinersen, marketed as Spinraza, is a medication used in treating spinal muscular atrophy (SMA), a rare neuromuscular disorder. In December 2016, it became the first approved drug used in treating this disorder.

Sutimlimab, sold under the brand name Enjaymo, is a monoclonal antibody that is used to treat adults with cold agglutinin disease (CAD). It is given by intravenous infusion. Sutimlimab prevents complement-enhanced activation of autoimmune human B cells in vitro.

<span class="mw-page-title-main">CRISPR Therapeutics</span> Swiss-American biotechnology company

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, Exagamglogene autotemcel, or exa-cel, has been submitted for regulatory approval in 2023.

Gapmers are short DNA antisense oligonucleotide structures with RNA-like segments on both sides of the sequence. These linear pieces of genetic information are designed to hybridize to a target piece of RNA and silence the gene through the induction of RNase H cleavage. Binding of the gapmer to the target has a higher affinity due to the modified RNA flanking regions, as well as resistance to degradation by nucleases. Gapmers are currently being developed as therapeutics for a variety of cancers, viruses, and other chronic genetic disorders.

Tofersen, sold under the brand name Qalsody, is a medication used for the treatment of amyotrophic lateral sclerosis (ALS). Tofersen is an antisense oligonucleotide that targets the production of superoxide dismutase 1, an enzyme whose mutant form is commonly associated with ALS. It is administered as an intrathecal injection into the spinal cord.

References

  1. ↑ "Brett P Monia Chief Executive Officer/Co-Founder, Ionis Pharmaceuticals Inc". www.bloomberg.com. Retrieved 20 May 2022.
  2. ↑ "Elizabeth L. Hougen Chief Financial Officer & Executive VP-Finance, Ionis Pharmaceuticals, Inc". www.wsj.com. Retrieved 20 May 2022.
  3. ↑ "Ionis announces changes to its board of directors at annual meeting of stockholders". www.prnewswire.com (Press release). Retrieved 20 May 2022.
  4. 1 2 "Ionis Pharmaceuticals, Inc. 2022 Form 10-K Annual Report". U.S. Securities and Exchange Commission. February 22, 2023.
  5. 1 2 Fikes, Bradley (December 18, 2015). "From Isis Pharma to Ionis" . The San Diego Union-Tribune .
  6. ↑ Crooke, Stanley T. (July 21, 2011). "The Isis manifesto". Bioentrepreneur. doi: 10.1038/bioe.2011.7 .
  7. ↑ Fisher, Lawrence M. (March 8, 1992). "Making a Difference; A Green Light for Isis" . The New York Times .
  8. ↑ Fisher, Lawrence M. (December 29, 1995). "Isis Drops Human Trials of a Genetic Drug" . The New York Times .
  9. ↑ Jarvis, Lisa M. (April 17, 2006). "Back In The Game". Chemical & Engineering News.
  10. ↑ Workman, Karen (November 20, 2015). "When You're Named Isis for the Goddess, Not the Terror Group". The New York Times .
  11. ↑ "Ionis Pharma Spins Out Lipid Disorder Unit Akcea with Plans for IPO". Xconomy . March 27, 2017.
  12. ↑ Katzung, Bertram G. (2006). Basic and Clinical Pharmacology. New York: S&P Global. p. 817. ISBN   978-0-07-145153-6.
  13. 1 2 Bubela, Tania; McCabe, Christopher (July 21, 2014). "Value-Engineered Translation: Developing Biotherapeutics That Align With Health-System Needs". American Journal of Managed Care.
  14. 1 2 3 Jiang, Kevin (February 19, 2013). "Biotech comes to its 'antisenses' after hard-won drug approval : Spoonful of Medicine". Nature Medicine: Spoonful of Medicine Blog.
  15. ↑ "Public Statement on Vitravene (fomiversen): Withdrawal of the Marketing Authorization in the European Union" (PDF). European Medicines Agency. August 6, 2002.
  16. ↑ Filmore, David (June 2004). "Assessing antisense" (PDF). Modern Drug Discovery.
  17. 1 2 3 4 Offord, Catherine (December 1, 2016). "Oligonucleotide Therapeutics Near Approval". The Scientist .
  18. ↑ "Company News; Isis Pharmaceuticals to Cut 40% of Workforce" . The New York Times . Bloomberg News. January 11, 2005.
  19. ↑ Pollack, Andrew (September 7, 2007). "Two Biotech Companies Agree to Form a Joint Venture" . The New York Times .
  20. ↑ Pollack, Andrew (January 8, 2008). "Genzyme Wins Cholesterol Drug Deal" . The New York Times .
  21. ↑ "EMA committee shoots down Sanofi's cholesterol drug mipomersen". FierceBiotech. December 14, 2012.
  22. ↑ "Refusal of the marketing authorisation for Kynamro (mipomersen)" (PDF). European Medicines Agency. March 21, 2013.
  23. ↑ Fikes, Bradley J. (January 11, 2016). "Ionis takes back heart drug Kynamro" . San Diego Union Tribune .
  24. ↑ "Ionis Sells Kynamro Rights to Kastle for Up to $95M+ Biotech from Bench to Business". Genetic Engineering News. May 3, 2016.
  25. ↑ Grant, Charley (December 27, 2016). "Surprise Drug Approval Is Holiday Gift for Biogen" . The Wall Street Journal . ISSN   0099-9660.
  26. ↑ Garber, K (October 11, 2016). "Big win possible for Ionis/Biogen antisense drug in muscular atrophy". Nature Biotechnology. 34 (10): 1002–1003. doi:10.1038/nbt1016-1002. PMID   27727217. S2CID   37479367.
  27. ↑ Wadman, Meredith (December 23, 2016). "Updated: FDA approves drug that rescues babies with fatal neurodegenerative disease". Science . doi:10.1126/science.aal0476.
  28. ↑ Tarr, Peter (December 24, 2016). "CSHL FDA approval of life-saving SMA drug is hailed by its researcher-inventor at CSHL". Cold Spring Harbor Laboratory .
  29. ↑ Saltzman, Jonathan; Weisman, Robert (December 16, 2017). "At a UMass lab, a eureka moment" . The Boston Globe .
  30. ↑ "Biogen Shells Out $75M to Develop Ionis' Nusinersen after Positive Phase III Results". Genetic Engineering News. August 1, 2016.
  31. ↑ "Biogen and Ionis Pharmaceuticals Report Nusinersen Meets Primary Endpoint at Interim Analysis of Phase 3 ENDEAR Study in Infantile-Onset Spinal Muscular Atrophy" (Press release). Biogen. August 1, 2016.
  32. ↑ Gallagher, James (October 19, 2015). "Landmark Huntington's trial starts". BBC News .
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.